#ASH24: Newly diagnosed multiple myeloma

Stay up to date with the latest developments in multiple myeloma from the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US. Catch up with our live social media relating to newly diagnosed multiple myeloma here. 

CONGRESS | #ASH24 | Salomon Manier, Lille University Hospital discusses data from the IFM2017-03 trial which investigated a dexamethasone sparing regimen with dara and lenalidomide for frail ND #MultipleMyeloma. Median OS and PFS was significantly improved with DR. Median PFS… pic.twitter.com/9WxFAeMzVo

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | @EliasKarlMa University Hospital Heidelberg shares the final PFS analysis from part I of the GMMG-HD7 trial of Isa-VRd induction in TE ND #MultipleMyeloma. Isa-VRd resulted in a 30% reduction in the risk of progression or death compared with VRd, regardless of… pic.twitter.com/8XNk4Qe7Ve

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | Maria- Victoria Mateos @mvmateos @usal discusses the impact of daratumumab at induction and/or consolidation in elderly fit ND #MultipleMyeloma. After 18 cycles, a higher MRD neg rate was observed in pts treated with KRd or D-KRd, compared with SoC VMP-Rd.… pic.twitter.com/4UUovOw33O

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | Laahn Foster @UVA presents an analysis of the phase III AURIGA study of daratumumab-lenalidomide maintenance in NDMM following transplant; concluding that D-R resulted in a PFS and MRD neg conversion benefit, including in those with high-risk disease.
Follow… pic.twitter.com/SZBBI1kM7O

— Multiple Myeloma Hub (@MM_Hub) December 9, 2024

CONGRESS | #ASH24 | Pieter Sonneveld, Erasmus MC Cancer Institute shares the long-term follow-up data from EMN02/HOVON95. Consolidation with VRd resulted in improved OS, with the highest OS observed in patients with CR at any time from the 2nd randomization.
Follow our live feed… pic.twitter.com/8nYLaxLHO4

— Multiple Myeloma Hub (@MM_Hub) December 9, 2024

CONGRESS | #ASH24 | Saad Z. Usmani @szusman @MSKCancerCenter shares an updated interim analysis from the DREAMM-9 trial of belantamab mafodotin in combination with SoC in TI NDMM. Across dosing schedules, ORR ranged from 71-100%, higher starting doses of belamaf were associated… pic.twitter.com/066NJD5qJP

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | Elena Zamagni @Unibo presents the latest dafety data from the MajesTEC-4 trial of teclistamab in combination with lenalidomide as maintenance following ASCT. Incidence of Grade 3/4 neutropenia at 6mo was 81.3%, 56.3%, and 40% in cohorts 1, 2, and 3,… pic.twitter.com/xcGWcSga3i

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | Marc Raab @RaabMarc @HDMyeloma shares the latest data from the MajesTEC-5 trial of teclistamab-based induction regimens in TE ND #MultipleMyeloma. MRD neg was observed in all patients at C3 and maintained into C6 for all evaluable patients. Grade 3/4… pic.twitter.com/OdOIf9Ejwu

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Evangelos Terpos @uoaofficial discusses a novel CTC-based prognostic algorithm for patients with NDMM.
Incorporating a 0.02% CTC cutoff with R-ISS and PCS creates a new stratification system with enhanced predictive and prognostic value.
Follow… pic.twitter.com/YUYplLJs6p

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Noemi Puig @usal highlights results from an analysis of paired serum and BM samples from TE patients with NDMM enrolled in the GEM2012MENOS65, GEM2014MAIN, and GEMCESAR clinical trials.
Findings suggest that mass spectrometry surpasses the… pic.twitter.com/dm9Y17Erbv

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@LucaBertamini @erasmusmcblood presents results from a circulating tumor cell sub-study of the phase III PERSEUS trial.
High circulating tumor cells were associated with a worse prognosis in patients with NDMM. The addition of daratumumab to VRd… pic.twitter.com/dj2MuRLPYM

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@EliasKarlMai @uniklinik_hd presents results from a landmark analysis of phase III GMMG-HD7 trial assessing the impact of induction regimen and post-induction and post-transplant MRD on PFS.
Post-induction and post-transplantation MRD negativity… pic.twitter.com/rf71hvUQXr

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Luciano J. Costa @End_myeloma @UABDeptMed highlights results from an analysis of patients with NDMM treated with Dara-KRd plus auto-HSCT in the MASTER trial and Dara-VRd plus auto-HSCT from an institutional database.
Patients with MRD progression… pic.twitter.com/RveFRHSBQW

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Sonja Zweegman @amsterdamumc presents results from an MRD analysis of the phase III CEPHEUS trial.
D-VRd resulted in higher rates of MRD negativity, and improved PFS in both MRD-negative and MRD-positive patients vs VRd.
Follow our live feed for… pic.twitter.com/Zh1iZzwsrA

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Panagiotis Malandrakis @uoaofficial shares findings from a prospective study assessing MRD-related and survival outcomes in patients with NDMM who discontinued lenalidomide maintenance therapy post-auto-HSCT after sustained MRD negativity for 3… pic.twitter.com/u0aRS2G3Iw

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | Joao Tadeu Damian Souto Filho @medicinacampos shares data comparing dara-based quads versus triplet induction regimens in TE ND #MultipleMyeloma. There were a 40% reduction in the risk of death with quads and 51% reduction of the risk of progression compared… pic.twitter.com/ixPtUMIAUg

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | Smith Giri @smith__giri @UABDeptMed shares data on the optimal MRD-based endpoint for treatment cessation for upfront quadruplet therapy in ND #MultipleMyeloma; concluding that sustained MRD<10-5 is the best fitting model to guide treatment cessation.
Follow… pic.twitter.com/XNuTXscazl

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | Xinhe Shan @EinsteinMed shares data from the CoMMpass study of the outcomes in patients with functional HR #MultipleMyeloma with and without HR features at diagnosis. Functional HR pts had worse OS, median TTP was similar between the 2 groups.
Follow our live… pic.twitter.com/Gs2KMoaMMC

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | Maximilian Merz @UniLeipzig discusses the impact of clinal heterogeneity in ND TE #MultipleMyeloma, from a subgroup analysis of GMMG-HD6; concluding that subclones are very common, particularly in patients with HR main clones. The clonal hierarchy is also… pic.twitter.com/TfgOalceoT

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | Jean-Sébastien Claveau @MayoClinic presents data from a study which assessed the need for repeating biomarkers to confirm PD; concluding confirmatory results are not necessary for patients with two biomarkers meeting progression criteria concurrently, as the… pic.twitter.com/HgstGy96mr

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | @RahulBanerjeeMD @UWMedicine @fredhutch discusses the rationale for moving toward urine-free response criteria in #MultipleMyeloma, showing little discordance between urine and urine-free response data, with a higher number of patients being evaluable for… pic.twitter.com/8hQSBc30Ud

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | POSTER | @AjayNookaMD @WinshipAtEmory presents safety and efficacy results for talquetamab in combination with dara and len in ND #MultipleMyeloma from the Monumental-2 study.
The tal-DR combination regimen demonstrated promising and rapid response rates in… pic.twitter.com/ZMS7n8Mr0S

— Multiple Myeloma Hub (@MM_Hub) December 13, 2024